Fig. 3: Molecular lipid signatures of IBD.

Variable selection of diagnostic lipidomic signatures using the SCAD model in the discovery cohort (N = 94). The bars represent the effect estimates (Beta [95% CI]) of the corresponding molecular lipids selected by the model during fivefold cross-validation. The left and right lines of the boxes indicate the first and third quartiles, the lines in the middle represent the median, and the whiskers extending to the most extreme points within 1.5 times the IQR. Information about the variable importance projection (VIP, %) for each molecular lipid is provided to the right side of each forest plot. a In the comparison of IBD vs SC, a diagnostic lipidomics signature consisting of 30 molecular lipids was selected. b In the comparison of CD vs SC, a lipidomic signature comprising 32 molecular lipids was selected. c In the comparison of UC vs SC, a diagnostic lipidomic signature composed of 19 molecular lipids was selected. d Distribution of lipid classes among the 169 lipids that were detected and annotated in both the discovery and validation cohort (N = 117). e Venn diagram showing the overlap of molecular lipids among the group comparisons: CD vs SC, and UC vs SC. IBD inflammatory bowel disease, CD Crohn’s disease, UC ulcerative colitis, SC symptomatic controls, BMI body mass index, hsCRP high-sensitivity C-reactive protein, LacCer(d18:1/16:0) lactosyl ceramide (d18:1/16:0); PC(18:0p/22:6), phosphatidylcholine (18:0p/22:6). Source data are provided as a Source Data file.